These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 32719489)
1. Therapeutic efficacy of antisense oligonucleotides in mouse models of CLN3 Batten disease. Centa JL; Jodelka FM; Hinrich AJ; Johnson TB; Ochaba J; Jackson M; Duelli DM; Weimer JM; Rigo F; Hastings ML Nat Med; 2020 Sep; 26(9):1444-1451. PubMed ID: 32719489 [TBL] [Abstract][Full Text] [Related]
2. A tailored Cln3 Langin L; Johnson TB; Kovács AD; Pearce DA; Weimer JM Sci Rep; 2020 Jun; 10(1):10591. PubMed ID: 32601357 [TBL] [Abstract][Full Text] [Related]
3. A novel c.1135_1138delCTGT mutation in CLN3 leads to juvenile neuronal ceroid lipofuscinosis. Drack AV; Miller JN; Pearce DA J Child Neurol; 2013 Sep; 28(9):1112-6. PubMed ID: 23877479 [TBL] [Abstract][Full Text] [Related]
4. Protracted CLN3 Batten disease in mice that genetically model an exon-skipping therapeutic approach. Centa JL; Stratton MP; Pratt MA; Osterlund Oltmanns JR; Wallace DG; Miller SA; Weimer JM; Hastings ML Mol Ther Nucleic Acids; 2023 Sep; 33():15-27. PubMed ID: 37359347 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of phosphodiesterase-4 inhibitors in juvenile Batten disease (CLN3). Aldrich A; Bosch ME; Fallet R; Odvody J; Burkovetskaya M; Rama Rao KV; Cooper JD; Drack AV; Kielian T Ann Neurol; 2016 Dec; 80(6):909-923. PubMed ID: 27804148 [TBL] [Abstract][Full Text] [Related]
6. Age-dependent therapeutic effect of memantine in a mouse model of juvenile Batten disease. Kovács AD; Saje A; Wong A; Ramji S; Cooper JD; Pearce DA Neuropharmacology; 2012 Oct; 63(5):769-75. PubMed ID: 22683643 [TBL] [Abstract][Full Text] [Related]
7. Novel CLN3 mutation predicted to cause complete loss of protein function does not modify the classical JNCL phenotype. Kwon JM; Rothberg PG; Leman AR; Weimer JM; Mink JW; Pearce DA Neurosci Lett; 2005 Oct; 387(2):111-4. PubMed ID: 16087292 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological Effects on Ceroid Lipofuscin and Neuronal Structure in Cln3 Brenneman DE; Pearce DA; Kovacs A; DeFrees S J Mol Neurosci; 2017 Sep; 63(1):100-114. PubMed ID: 28812237 [TBL] [Abstract][Full Text] [Related]
9. Partial correction of the CNS lysosomal storage defect in a mouse model of juvenile neuronal ceroid lipofuscinosis by neonatal CNS administration of an adeno-associated virus serotype rh.10 vector expressing the human CLN3 gene. Sondhi D; Scott EC; Chen A; Hackett NR; Wong AM; Kubiak A; Nelvagal HR; Pearse Y; Cotman SL; Cooper JD; Crystal RG Hum Gene Ther; 2014 Mar; 25(3):223-39. PubMed ID: 24372003 [TBL] [Abstract][Full Text] [Related]
10. Cln3-mutations underlying juvenile neuronal ceroid lipofuscinosis cause significantly reduced levels of Palmitoyl-protein thioesterases-1 (Ppt1)-protein and Ppt1-enzyme activity in the lysosome. Appu AP; Bagh MB; Sadhukhan T; Mondal A; Casey S; Mukherjee AB J Inherit Metab Dis; 2019 Sep; 42(5):944-954. PubMed ID: 31025705 [TBL] [Abstract][Full Text] [Related]
11. Transcript and in silico analysis of CLN3 in juvenile neuronal ceroid lipofuscinosis and associated mouse models. Chan CH; Mitchison HM; Pearce DA Hum Mol Genet; 2008 Nov; 17(21):3332-9. PubMed ID: 18678598 [TBL] [Abstract][Full Text] [Related]
13. Gene Therapy Targeting the Inner Retina Rescues the Retinal Phenotype in a Mouse Model of CLN3 Batten Disease. Kleine Holthaus SM; Aristorena M; Maswood R; Semenyuk O; Hoke J; Hare A; Smith AJ; Mole SE; Ali RR Hum Gene Ther; 2020 Jul; 31(13-14):709-718. PubMed ID: 32578444 [TBL] [Abstract][Full Text] [Related]
14. Altered gene expression in the eye of a mouse model for batten disease. Chattopadhyay S; Kingsley E; Serour A; Curran TM; Brooks AI; Pearce DA Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):2893-905. PubMed ID: 15326100 [TBL] [Abstract][Full Text] [Related]
18. A novel porcine model of CLN3 Batten disease recapitulates clinical phenotypes. Swier VJ; White KA; Johnson TB; Wang X; Han J; Pearce DA; Singh R; Drack AV; Pfeifer W; Rogers CS; Brudvig JJ; Weimer JM Dis Model Mech; 2023 Aug; 16(8):. PubMed ID: 37305926 [TBL] [Abstract][Full Text] [Related]
19. Batten disease: evaluation of CLN3 mutations on protein localization and function. Haskell RE; Carr CJ; Pearce DA; Bennett MJ; Davidson BL Hum Mol Genet; 2000 Mar; 9(5):735-44. PubMed ID: 10749980 [TBL] [Abstract][Full Text] [Related]
20. Lack of specificity of antibodies raised against CLN3, the lysosomal/endosomal transmembrane protein mutated in juvenile Batten disease. Nelson T; Pearce DA; Kovács AD Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 29089465 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]